CellCept and Myfortic Are Associated with the Development of Progressive Multifocal Leukoencephalopathy (PML)
2008-07-07
The U.S. food and drug administration (FDA), the equivalents of the Saudi food and drud authority (SFDA) announced that Novartis and Roche have issued a dear healthcare professional letters to inform them that use of Myfortic (mycophenolic acid) and CellCept (mycophenolate mofetil) , medicines used to prevent organ rejection are associated with the development of Progressive Multifocal Leukoencephalopathy (PML) .